Lowdell Mark William 的 Form 4/A 修正申報
修正Inmune Bio, Inc.（INMB），2024/4/24 申報
- 申報編號
- 0001213900-24-035721
- 申報時間
- 2024/4/24 14:08 ET
- 交易日
- 2024/4/19
- 申報延遲
- 5 天
- 10b5-1 計畫
- 沒有勾選
- 原始申報日
- 2024/4/23
這份申報列了 1 筆非衍生性交易、1 筆衍生性交易。公開市場買進合計 $12.0 萬。交易後 5 天申報。
這份修正申報取代了 0001213900-24-035472（2024/4/23 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Lowdell Mark WilliamCIK 0001767037 | 高階主管（科學長）、持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/4/19 | Common Stock | P買進取得 | +14,423 | $8.32 | +$119,999.36 | 1,510,806 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/4/19 | Common Stock | P買進取得 | +14,423 | $0.125 | +$1,802.88 | 14,423 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $121,802.24 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant.
備註
The original Form 4, filed on April 23, 2024 is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the transaction as an award in column 3 of Table I and column 4 of table II instead of a purchase. The reporting person purchased the securities in a registered direct transaction from the Company.